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In the present study, two phytochemicals - ursolic acid (UA) and luteolin-7-glucoside 26 
(L7G) - were assessed in vivo in healthy rats regarding effects on plasma glucose and 27 
lipid profile (total cholesterol, HDL and LDL), as well as liver glycogen content, in 28 
view of their importance in the aetiology of diabetes and associated complications. Both 29 
UA and L7G significantly decreased plasma glucose concentration. UA also 30 
significantly increased liver glycogen levels accompanied by phosphorylation of 31 
glycogen synthase kinase-3 (GSK3). The increase in glycogen deposition induced by 32 
UA (mediated by GSK3) could have contributed for the lower plasma glucose levels 33 
observed. Both compounds significantly lowered total plasma cholesterol and low-34 
density lipoprotein levels, and in addition UA increased plasma high-density lipoprotein 35 
levels. Our results show that particularly UA may be useful in preventable strategies for 36 
people at risk of developing diabetes and associated cardiovascular complications by 37 
improving plasma glucose levels and lipid profile, as well as by promoting liver 38 
glycogen deposition. 39 
 40 
Keywords: Lamiaceae species; ursolic acid; luteolin-7-glucoside; lipid profile; liver 41 
glycogen; functional foods. 42 
 43 
INTRODUCTION 44 
Glucose is a major source of energy for humans and its concentration in the blood is 45 
tightly regulated by the pancreatic hormone insulin. Diabetes mellitus is a metabolic 46 
disorder characterised by chronically elevated blood glucose associated with the 47 
impairment of insulin secretion and/or a deficient action on peripheral tissues (Klover 48 

































































and Mooney, 2004). Once absorbed after a meal, rising plasma glucose stimulates 49 
insulin release and, in tissues such as liver and skeletal muscle, glucose uptake and 50 
glycogen synthesis is promoted, which constitutes an important mechanism of 51 
glycaemic control. In diabetic patients this mechanism of plasma glucose clearance is 52 
less efficient, originating hyperglycaemia (Postic et al., 2004). 53 
In addition to hyperglycaemia, diabetic patients often show an abnormal plasma 54 
lipid profile with high levels of low-density lipoprotein (LDL) cholesterol and lower 55 
than desirable levels of high-density lipoprotein (HDL) cholesterol, a combination 56 
implicated in the development of cardiovascular complications (Kastelein, 2005; 57 
Mooradian, 2009). Although not totally elucidated, insulin resistance have been 58 
implicated in the pathogenesis of diabetic dyslipidemia (Mooradian, 2009). By reducing 59 
insulin resistance as well as by lowering plasma glucose and LDL cholesterol on the 60 
one hand, and increasing HDL cholesterol levels on the other, an improvement of the 61 
diabetic health status may be achieved that would also help prevent cardiovascular 62 
complications. The fact that the number of cases of diabetes is increasing worldwide 63 
and the realisation that the therapeutic drugs currently in use are not a hundred percent 64 
efficient motivates the search for new active principles among natural compounds from 65 
medicinal plants. In addition, type 2 diabetes mellitus (T2DM) has been considered a 66 
preventable disease through lifestyle changes that includes diet interventions (Costacou 67 
and Mayer-Davis, 2003). Natural compounds may be well accepted and considered for 68 
the production of enriched added value functional foods and included in dietary 69 
strategies for prevention of T2DM and/or health improvement of diabetic patients. 70 
Based on ethnopharmacological data and pharmacological studies, the genus 71 
Salvia (Lamiaceae family) has been suggested to possess antidiabetic properties 72 

































































(Baricevic and Bartol, 2000). Previous studies have demonstrated Salvia officinalis tea 73 
to decrease fasting blood glucose levels in healthy animals (Lima et al., 2006a). 74 
Moreover, methanolic and ethanolic extracts of S. officinalis as well as an infusion of S. 75 
fruticosa showed to have hypoglycaemic effects in diabetic experimental animals 76 
(Perfumi et al., 1991; Alarcon-Aguilar et al., 2002; Eidi et al., 2005). Luteolin-7-77 
glucoside (L7G) and ursolic acid (UA) (Fig.1) are a flavonoid and a triterpenoid, 78 
respectively, present in many plants and particularly abundant in Salvia species (Lima et 79 
al., 2005; Janicsak et al., 2006), and may contribute to these plants’ biological effects 80 
(Baricevic and Bartol, 2000). 81 
Many effects attributed to natural compounds, in particular to flavonoids, result 82 
from in vitro studies, which may not be observed in vivo due to biotransformation 83 
reactions and low bioavailability. Therefore, it is of great interest to assess possible 84 
beneficial effects of isolated natural compounds in in vivo studies. 85 
In the present study, the effects of L7G and UA were monitored in vivo in 86 
healthy rats regarding plasma glucose, plasma lipid profile (total cholesterol, HDL and 87 
LDL) and liver glycogen content in view of their importance in the aetiology of diabetes 88 
and associated complications. The expression of glycogen synthase kinase-3 (GSK3) in 89 
the liver was also measured since it is an important enzyme involved in the insulin 90 
sensitive glycogen synthesis pathway (Lee and Kim, 2007).  91 
 92 
MATERIAL AND METHODS 93 
Chemicals. Bradford Reagent and ursolic acid were purchased from Sigma-Aldrich (St. 94 
Louis, MO, USA). Luteolin-7-O-glucoside was purchased from Extrasynthese (Genay, 95 
France). Glucofix was purchased from A. Menarini Diagnostics (Firenze, Italy). 96 

































































Commercial kits to measure total cholesterol, LDL cholesterol and HDL cholesterol 97 
were acquired from Spinreact (Girona, Spain). All others reagents were of analytical 98 
grade. 99 
 100 
Animals. Male Wistar rats (6 weeks old) were purchased from Charles River 101 
Laboratories (Barcelona, Spain) and acclimated to our laboratory animal facilities for at 102 
least one week before the start of the experiment. During the experimental period, 103 
animals were maintained on a natural light/dark cycle at 20 ± 2ºC and given food and 104 
tap water ad libitum. Animals were kept and handled in accordance with our university 105 
regulations that follow NIH guidelines (NIH Publication No. 80-23; revised 1978) for 106 
the experimental use and care of laboratory animals. 107 
 108 
Experimental design. Fifteen male Wistar rats were divided into three groups: control; 109 
UA-supplemented diet and L7G-supplemented diet. Test compounds were administered 110 
orally, once a day, for 7 consecutive days, well mixed in a small piece of food (control 111 
group received vehicle only) in a daily dose of 2 mg of compound per kg of animal 112 
body weight. The dose of the compound administered was based on estimations of 113 
physiological concentrations by Hertog et al. (1993). During the experiment water was 114 
given ad libitum to the animals. The administration of each compound did not change 115 
food and beverage consumption, as well as animal body weights when compared to the 116 
control. At the end of the treatment, animals were sacrificed by decapitation. Blood 117 
samples were collected and plasma kept for the measurement of glucose and lipid 118 
parameters (total cholesterol, LDL cholesterol, HDL cholesterol).  Liver samples were 119 
also collected, frozen in liquid nitrogen and kept at -80ºC for further analyses.   120 


































































Quantification of plasma glucose, total cholesterol, low-density lipoprotein and 122 
high-density lipoprotein cholesterol levels. The amount of glucose in rat plasma was 123 
measured using a colorimetric enzymatic method - Glucofix - following manufacturer’s 124 
specifications. 125 
The plasma total cholesterol, LDL cholesterol and HDL cholesterol levels were 126 
measured in rat plasma using spectrophotometric commercial kits from Spinreact 127 
following manufacturer’s specifications. 128 
 129 
Liver glycogen quantification. The liver glycogen content was quantified by the 130 
amyloglucosidase method as described by Keppler and Decker (1974). Dilutions of the 131 
liver homogenate were used to ensure that the determination was done within the linear 132 
phase. Liver glycogen content is expressed in µmol glucose per g of liver. 133 
 134 
Liver homogenates and western blot analysis. A piece of liver was homogenized in 135 
cold lysis buffer (0.5% NP-40 in 50 mM Na2HPO4, pH 7.4, 150 mM NaCl2, 2 mM 136 
EDTA,) containing protease (1 mM phenylmethylsulfonyl fluoride, 10 µg/ml aprotinin) 137 
and phosphatase (20 mM NaF, 20 mM orthovanadate) inhibitors added just before use. 138 
The homogenate was then centrifuged at 10,000 ×g at 4ºC for 10 min and the 139 
supernatant collected. The amount of protein was measured using Bradford Reagent 140 
following manufacturer instructions, using BSA as a standard.  141 
For western blot, 25 µg of protein of each sample were separated by SDS-PAGE, 142 
transferred onto Hybond-P polyvinylidene difluoride membranes (GE Healthcare, UK) 143 
and then blocked in 5% (w/v) non-fat dry milk in TPBS (0.05% (v/v) Tween 20 in 144 

































































PBS). The membranes were then probed using a rabbit polyclonal antibody to rat 145 
phospho-GSK3α/β (Ser21/9) (Cell Signalling Technology, Inc., Danvers, MA, USA), 146 
mouse monoclonal antibody to rat total GSK3α/β (Santa Cruz Biotechnology, Inc., 147 
Santa Cruz, CA, USA), and mouse monoclonal anti-β-actin (Sigma-Aldrich, Inc). After 148 
incubation with the secondary antibody, immunoreactive bands were developed using a 149 
chemiluminescence detection system, the Chemi Doc XRS (BioRad Laboratories, Inc.). 150 
Band area intensity was quantified using the Quantity One software from Bio-Rad. 151 
 152 
Statistical Analysis.  Results are expressed as the mean ± standard error of the mean 153 
(SEM) for the number of animals in the group. Statistical significances between groups 154 
were determined using the one-way ANOVA followed by the Newman-Keuls multiple 155 
comparison test. P value < 0.05 was considered statistically significant. 156 
 157 
RESULTS AND DISCUSSION 158 
In the present study, we aimed to identify active principles among plants’ 159 
constituents to be used in dietary approaches that offer low-cost alternatives in 160 
interventions to prevent diabetes or limit its progression. For that, two individual 161 
constituents (UA and L7G) present in Salvia species, plants to which antidiabetic 162 
properties are attributed, were used at relatively low concentrations (to mimic the 163 
normal intake in the human diet) in order to evaluate in vivo effects on plasma glucose, 164 
lipid profile and liver glycogen in healthy rats. 165 
After 7 days treatment (with 2 mg.kg-1.day-1 of UA or L7G), plasma glucose 166 
levels were significantly decreased from 176.1 mg/dl (9.78 mM) in control group to 167 
158.1 mg/dl (8.78 mM) in UA and 157.6 mg/dl (8.76 mM) in L7G (Fig. 2A). A 168 

































































previous study reported that UA prevents glucose intolerance in high-fat-fed mice 169 
(Jayaprakasam et al., 2006), corroborating our data that this triterpenoid may interfere 170 
with glucose clearance mechanisms. UA and L7G also increased the glycogen content 171 
in liver, which was significant for UA (Fig. 2B). Therefore, the increase in glycogen 172 
deposition induced mainly by UA could have contributed for the lower plasma glucose 173 
levels observed. Recently, in vitro studies performed by Jung et al. (2007) in cultured 174 
adipocytes and CHO/IR cells showed that UA is an insulin sensitizer, leading to an 175 
increase in insulin receptor (IR)β auto-phosphorylation and a subsequent activation of 176 
downstream phosphatidylinositol 3-kinase (PI3K) signalling pathway activation. The 177 
activation of this pathway would result in phosphorylation and inactivation of GSK3, 178 
leading to an increase glycogen synthase activation and glycogen synthesis (Lee and 179 
Kim, 2007). In agreement with this, the increase of liver glycogen induced by UA 180 
observed in the present study was accompanied by an increase of liver phospho-GSK3 181 
expression (Fig. 3), indicating that in vivo this compound may also be activating IR and 182 
the PI3K signalling. It seems, therefore, that UA may be useful in the prevention of 183 
T2DM, and probably in its treatment where patients show a decrease in insulin response 184 
due to lower IR and insulin receptor substrate-1-phosphorylation with decreased PI3K 185 
activity (Goodyear et al., 1995; Pratipanawatr et al., 2001).  186 
Although to a smaller extent, L7G also induced the phosphorylation of GSK3 (P 187 
= 0.06, Fig. 3). Flavonoids have shown different effects with respect to the regulation of 188 
insulin signalling pathway, which suggest the effects may depend on compounds’ 189 
concentration and be cell type and context specific. For example, certain flavonoids 190 
such as luteolin (the aglycone of L7G), quercetin, apigenin and kaempferol showed 191 
inhibitory effects on insulin signalling pathway in mouse adipose cells by suppressing 192 

































































insulin receptor phosphorylation and subsequent inhibition of PI3K and Akt activation 193 
(Nomura et al., 2008). Moreover, in colon cancer cells the flavonoids luteolin and 194 
quercetin, as well as the triterpenoid UA, inhibited the PI3K/Akt pathway (Xavier et al., 195 
2009). On the other hand, kaempferol-3-neohesperidoside stimulates glycogen synthesis 196 
in rat soleus muscle, possibly through PI3K/GSK3 pathway (Cazarolli et al., 2009). As 197 
well, epigallocatechin-gallate showed stimulatory effects on insulin pathway inhibiting 198 
gluconeogenesis and GSK3 activity in hepatocytes through the activation of PI3K/Akt-199 
dependent pathway (Waltner-Law et al., 2002; Lin and Lin, 2008).  200 
In addition to plasma glucose, plasma lipids are important predictors of T2DM 201 
progression and development of cardiovascular complications. In order to assess 202 
possible effects of the UA and L7G on lipid profile, levels of plasma lipids (total 203 
cholesterol, LDL and HDL) were measured. As shown in Fig. 4A, total plasma 204 
cholesterol levels were significantly reduced by both treatments (by 28.5% with UA and 205 
by 29.2% with L7G), which was accompanied by a consistent reduction of plasma LDL 206 
levels (by 36.2% and 39.5%, respectively, Fig. 4B). In addition, a 51.1% increase of 207 
HDL plasma levels was induced by UA treatment while L7G was not active on this 208 
parameter (Fig. 4C). Both UA and L7G increased significantly the HDL/total 209 
cholesterol ratio (HTR in %), although effects were more pronounced for UA (Fig. 4D). 210 
Thus, both compounds showed relevant effects on the control of plasma lipids, by 211 
diminishing total cholesterol and LDL with UA additionally increasing HDL levels. 212 
Interestingly, in a pilot study where human volunteers at risk to develop T2DM were 213 
treated with S. officinalis tea (L7G being the main flavonoid present in the extract) an 214 
improvement of lipid profile was also observed by decreasing plasma total cholesterol 215 
and LDL while increasing HDL levels (Sá et al., 2009). Statins and fibrates are 216 

































































pharmaceutical drugs currently used in the treatment of diabetic dyslipidaemia 217 
(Kastelein, 2005). Since statins act mainly by reducing LDL cholesterol levels whereas 218 
fibrates increase HDL cholesterol levels, combination therapies have been used to 219 
control dyslipidaemia and to diminish the risk of cardiovascular diseases and associated 220 
morbidity and mortality (Kastelein, 2005). UA administered alone produced this double 221 
effect in rats, which warrants future studies in diabetic/obese animals and humans.  222 
Thiazolidinediones (TZDs), also used in the treatment of T2DM patients, act 223 
through peroxisome proliferator-activated receptor-γ improving insulin sensitivity and 224 
lipid profile (Levetan, 2007; Kersten, 2008). In addition, recently Ciaraldi et al. (2006) 225 
showed that the TZD troglitazone also inhibited GSK3 in skeletal muscle of obese 226 
T2DM patients. In the present study, although probably through different mechanisms, 227 
UA was also effective on both the inhibition of GSK3 activity (with a concomitant rise 228 
in liver glycogen synthesis) and on the improvement of lipid profile. Since insulin 229 
resistance may have a central role in the development of diabetic dyslipidemia 230 
(Mooradian, 2009), the possible induction of insulin sensitivity by UA may be also 231 
indirectly involved in the improvement of lipid profile. 232 
 The effects of UA and L7G, in particular those of UA, suggest, therefore, that 233 
these compounds could contribute positively to prevention and also the control of 234 
dyslipidaemia and hyperglycaemia observed in T2DM. These beneficial effects of UA 235 
and L7G may be assisted by their known effects on the enhancement of cellular 236 
antioxidant defences (Lima et al., 2006b; Yin and Chan, 2007; Ramos et al., 2008) 237 
known to be overwhelmed by the inherent excess of reactive oxygen species production 238 
observed in diabetes. 239 

































































In conclusion, we observed that L7G showed effects in vivo on plasma glucose 240 
and lipid profile, whereas UA in addition to these effects also increased liver glycogen 241 
deposition and plasma HDL levels. Considering that T2DM and cardiovascular diseases 242 
can be prevented through lifestyle changes including dietary strategies, these two 243 
phytochemicals may be good candidates for the production of functional foods and food 244 
supplements due to their beneficial properties on relevant parameters for the prevention 245 
and control of these disorders. In addition, since these compounds are present in many 246 
Salvia species, they may account for the health benefits attributed to this genus, in 247 
particular for its antidiabetic reputation. 248 
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FIGURE CAPTIONS  350 
 351 
Figure 1. Chemical structures of the compounds used in this study: the flavonoid 352 
luteolin-7-glucoside and the pentacyclic triterpenoid ursolic acid. 353 
   354 
Figure 2. Effect of 7 days diet supplied with the test compound (UA or L7G) on rat 355 
plasma glucose concentration (A), and liver glycogen content (B). Values are expressed 356 
as mean ± SEM (n = 5). **, P < 0.01 when compared with the control group. 357 
 358 
Figure 3. Western blot analysis of phospho-GSK3-β protein in liver homogenates of 359 
rats (A), with representative immunoblots and corresponding loading control (β-actin) 360 
from a pair of animals from each treatment (B). Values are expressed as mean ± SEM (n 361 
= 5). * P < 0.05 when compared with the control group. ª P = 0.06 when compared with 362 
the control group (in this case analysed by the Student t-test).  363 
 364 
Figure 4. Effects of 7 days diet supplied with the test compound (UA or L7G) on rat 365 
plasma total cholesterol (A), LDL cholesterol (B) and HDL cholesterol (C). HTR (%) = 366 
(HDL/Total cholesterol) × 100. Values are expressed as mean ± SEM (n = 5). ***, P < 367 
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Figure 1. Chemical structures of the compounds used in this study: the flavonoid luteolin-7-
glucoside and the pentacyclic triterpenoid ursolic acid.  
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Figure 2. Effect of 7 days diet supplied with the test compound (UA or L7G) on rat plasma glucose 
concentration (A), and liver glycogen content (B). Values are expressed as mean ± SEM (n = 5). 
**, P < 0.01 when compared with the control group.  
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Figure 3. Western blot analysis of phospho-GSK3-β protein in liver homogenates of rats (A), with 
representative immunoblots and corresponding loading control (β actin) from a pair of animals from 
each treatment (B). Values are expressed as mean ± SEM (n = 5). * P < 0.05 when compared with 
the control group. ª P = 0.06 when compared with the control group (in this case analysed by the 
Student t-test).  
80x85mm (300 x 300 DPI)  
 




































































Figure 4. Effects of 7 days diet supplied with the test compound (UA or L7G) on rat plasma total 
cholesterol (A), LDL cholesterol (B) and HDL cholesterol (C). HTR (%) = (HDL/Total cholesterol) × 
100. Values are expressed as mean ± SEM (n = 5). ***, P < 0.001; **, P < 0.01 and *, P < 0.05 
when compared with the control group.  
160x112mm (300 x 300 DPI)  
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